This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ having the formula:

- 2. (Withdrawn) The method of claim 1 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered orally.
- 3. (Withdrawn) The method of claim 1 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered parenterally.
- 4. (Withdrawn) The method of claim 1 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered transdermally.
- 5. (Withdrawn) The method of claim 1 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered topically.
- 6. (Withdrawn) The method of claim 1 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered in a dosage of from about $0.01\mu g/day$ to about $100~\mu g/day$.

7. (Withdrawn) A method of treating a disease selected from the group consisting of leukemia, colon cancer, breast cancer or prostate cancer comprising administering to a patient with said disease an effective amount of (20S)-1α-hydroxy-2-methylene-19-nor-vitamin D₃ having the formula:

- 8. (Withdrawn) The method of claim 7 wherein of (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered orally.
- 9. (Withdrawn) The method of claim 7 wherein of (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered parenterally.
- 10. (Withdrawn) The method of claim 7 wherein of (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered transdermally.
- 11. (Withdrawn) The method of claim 7 wherein of (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered in a dosage of from about $0.01\mu g/day$ to about $100 \mu g/day$.
- 12. (Withdrawn) A method of treating an autoimmune disease selected from the group consisting of multiple sclerosis, lupis, diabetes, mellitus, host versus graft reaction, and rejection of organ transplants, comprising administering to a patient

with said disease an effective amount of (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 having the formula:

- 13. (Withdrawn) The method of claim 12 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered orally.
- 14. (Withdrawn) The method of claim 12 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered parenterally.
- 15. (Withdrawn) The method of claim 12 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered transdermally.
- 16. (Withdrawn) The method of claim 12 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered in a dosage of from about $0.01\mu g/day$ to about $100~\mu g/day$.

- 4 -

17. (Withdrawn) A method of treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, asthma, and inflammatory bowel diseases, comprising administering to a patient with said disease an effective amount of $(20S)-1\alpha$ -hydroxy-2-methylene-19-nor-vitamin D_3 having the formula:

- 18. (Withdrawn) The method of claim 17 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered orally.
- 19. (Withdrawn) The method of claim 17 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered parenterally.
- 20. (Withdrawn) The method of claim 17 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered transdermally.
- 21. (Withdrawn) The method of claim 17 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered in a dosage of from about $0.01\mu g/day$ to about $100 \mu g/day$.

22. (Original) (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ having the formula:

23. (Withdrawn) A method of treating a skin condition selected from the group consisting of wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion which comprises administering to a patient with said skin condition an effective amount of $(20S)-1\alpha$ -hydroxy-2-methylene-19-nor-vitamin D_3 having the formula:

24. (Withdrawn) The method of claim 23 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered orally.

- 25. (Withdrawn) The method of claim 23 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered parenterally.
- 26. (Withdrawn) The method of claim 23 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered transdermally.
- 27. (Withdrawn) The method of claim 23 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered topically.
- 28. (Withdrawn) The method of claim 23 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered in a dosage of from about $0.01\mu g/day$ to about $100 \mu g/day$.
- 29. (Withdrawn) A method of treating a metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ having the formula:

- 30. (Withdrawn) The method of claim 29 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered orally.
- 31. (Withdrawn) The method of claim 29 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered parenterally.

- 32. (Withdrawn) The method of claim 29 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D₃ is administered transdermally.
- 33. (Withdrawn) The method of claim 29 wherein (20S)- 1α -hydroxy-2-methylene-19-nor-vitamin D_3 is administered in a dosage of from about $0.01\mu g/day$ to about $100 \mu g/day$.
- 34. (Withdrawn) The method of claim 29 where the disease is senile osteoporosis.
- 35. (Withdrawn) The method of claim 29 where the disease is postmenopausal osteoporosis.
- 36. (Withdrawn) The method of claim 29 where the disease is steroid-induced osteoporosis.
- 37. (Withdrawn) The method of claim 29 where the disease is low bone turnover osteoporosis.
- 38. (Withdrawn) The method of claim 29 where the disease is osteomalacia.
 - 39. (Withdrawn) A compound having the formula: